N-苯甲酰基-5’-O-(4,4-二甲氧基三苯甲基)-2’-O-[(叔丁基)二甲基硅基]腺苷-3’-(2-氰基乙基-N,N-二异丙基)亚磷酰胺 | 104992-55-4

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: N-苯甲酰基-5’-O-(4,4-二甲氧基三苯甲基)-2’-O-[(叔丁基)二甲基硅基]腺苷-3’-(2-氰基乙基-N,N-二异丙基)亚磷酰胺
• 中文别名: N-苯甲酰基-5'-O-(4,4-二甲氧基三苯甲基)-2'-O-[(叔丁基)二甲基硅基]腺苷-3'-(2-氰基乙基-N,N-二异丙基)亚磷酰胺；Bz-rA亚磷酰胺单体；Bz-rA 亚磷酰胺单体；DMT-2'-O-TBDMS-N6-苯甲酰基腺苷亚磷酰胺
• 英文名称: N⁶-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(tert-butyldimethylsilyl)adenosine 3'-O-(2-cyanoethyl N,N-diisopropylphosphoramidite)
• 英文别名: (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite；Bz-rA Phosphoramidite；N-[9-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-[tert-butyl(dimethyl)silyl]oxy-4-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxyoxolan-2-yl]purin-6-yl]benzamide
• CAS: 104992-55-4
• 化学式: C₅₃H₆₆N₇O₈PSi
• 分子量: 988.208
• InChiKey: FFXHNCNNHASXCT-RFMFGJHUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.05
• 重原子数：
  70
• 可旋转键数：
  22
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  164
• 氢给体数：
  1
• 氢受体数：
  13

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
: DMT-2′O-TBDMS-rA(bz) Phosphoramidite
Product name
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No 1272/2008
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Molecular Weight : 988,19 g/mol
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: -20 °C
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  5'-O-（4,4'-二甲氧基三苯甲基）-2'-O-叔丁基二甲基硅基-N6-苯甲酰基腺苷	5'-O-dimethoxytrityl-2'-O-tert-butyldimethylsilyl-N6-benzoyl adenosine	81265-93-2	C44H49N5O7Si	787.988
  ——	6-N-benzoyl-5'-O-(4,4'-dimethoxytrityl)adenosine	——	C38H35N5O7	673.725
  N6-苯甲酰基腺苷	N-benzoyladenosine	4546-55-8	C17H17N5O5	371.352
  ——	adenosine	1348775-39-2	C10H15N5O4	269.26

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	5'-O-DMTr-rA(Bz)p(CNE)dT-3'-O-Lev	1220703-63-8	C62H71N8O15PSi	1227.35
  ——	N(6)-(benzoyl)-2'-O-(tert-butyldimethylsilyl)adenosine 3'-(allyl 2-cyanoethyl phosphate)	1353637-05-4	C29H39N6O8PSi	658.723

反应信息

• 作为反应物：
  描述：

  N-苯甲酰基-5’-O-(4,4-二甲氧基三苯甲基)-2’-O-[(叔丁基)二甲基硅基]腺苷-3’-(2-氰基乙基-N,N-二异丙基)亚磷酰胺 在 水 、 三氟乙酸吡啶 、 叔丁胺 作用下， 以 乙腈 为溶剂， 反应 0.5h， 生成 (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate
  参考文献：
  名称：

  设计，合成和生物评价新型环腺苷一磷酸肌苷（cAIMP）类似物，可激活干扰素基因（STING）的刺激物。

  摘要：

  我们描述了新型STING激活环状二核苷酸，其组成核苷为腺苷和肌苷，并通过核糖取代，核苷酸间键合位置和磷酸修饰而变化。在体外哺乳动物细胞中，这些cAIMP类似物中的一些诱导的STING依赖性IRF和NF-κB途径信号传导比鼠类（DMXAA）或人（2'，3'-cGAMP）STING的参考激动剂要强。在人血液中体外，它们诱导I型干扰素（IFN）和促炎细胞因子：对于前者，3'，3'-cAIMP（9 ; EC 50 6.4μM）和类似物52 - 56（EC 50含有一个或两个2'-氟-2'-脱氧核糖和/或双硫代磷酸酯键的分子，其浓度为0.4-4.7μM）比2'，3'-cGAMP（EC 50为19.6μM）更有效。有趣的是，9比其连接异构体2'，3'-cAIMP（10），3'，2'-cAIMP（23）和2'，2'-cAIMP（27）诱导I型IFN的作用更强。最后，一些cAIMP类似物比2'，3'-cG

  DOI：

  10.1021/acs.jmedchem.6b01300
• 作为产物：
  描述：

  N6-苯甲酰基腺苷 在 吡啶 、 4-二甲氨基吡啶 、 silver nitrate 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 19.0h， 生成 N-苯甲酰基-5’-O-(4,4-二甲氧基三苯甲基)-2’-O-[(叔丁基)二甲基硅基]腺苷-3’-(2-氰基乙基-N,N-二异丙基)亚磷酰胺
  参考文献：
  名称：

  [EN] CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE
  [FR] COMPOSÉS DI-NUCLÉOTIDES CYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  揭示了环二核苷酸cGAMP类似物，合成这些化合物的方法，包括这些化合物的药物组合物，以及在医学治疗中使用这些化合物和组合物的用途。

  公开号：

  WO2017161349A1

文献信息

• [EN] CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING<br/>[FR] DINUCLÉOTIDES CYCLIQUES UTILISÉS EN TANT QU'AGONISTES DU STIMULATEUR DE LA SIGNALISATION DÉPENDANTE DU GÈNE DE L'INTERFÉRON
  申请人：UNIV TEXAS

  公开号：WO2018156625A1

  公开（公告）日：2018-08-30

  Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.

  本文披露了新的环二核苷酸化合物和组合物，以及它们作为药物治疗疾病的应用。还提供了调节免疫应答以及诱导干扰素基因激活剂（STING）依赖型I干扰素在人类或动物受试者中产生和共调控基因的方法，用于治疗癌症、尤其是转移性实体瘤和淋巴瘤、炎症、过敏和自身免疫疾病、传染病，以及作为抗病毒剂和疫苗佐剂的用途。
• [EN] CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS<br/>[FR] DINUCLÉOTIDES CYCLIQUES UTILISÉS EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019074887A1

  公开（公告）日：2019-04-18

  The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

  本发明涉及式(I)的化合物，其中所有取代基在此定义，以及包括本发明化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病的方法。
• [EN] DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS<br/>[FR] CONJUGUÉS D'ANTICORPS DC-SIGN COMPRENANT DES AGONISTES DE STING
  申请人：NOVARTIS AG

  公开号：WO2020092617A1

  公开（公告）日：2020-05-07

  Provided herein are immunoconjugates comprising an anti-DC-SiGN antibody conjugated to a STING agonist. Also disclosed are methods of making the immunoconjugates and methods of treating cancer using the immunoconjugates.

  本文件提供了包含抗-DC-SiGN抗体与STING激动剂偶联的免疫偶联物。还公开了制造免疫偶联物的方法以及使用免疫偶联物治疗癌症的方法。
• [EN] BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS LIGANDS PEPTIDIQUES BICYCLIQUES ET LEURS UTILISATIONS
  申请人：BICYCLERD LTD

  公开号：WO2019034866A1

  公开（公告）日：2019-02-21

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• [EN] BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS PEPTIDE-LIGAND BICYCLIQUE ET LEURS UTILISATIONS
  申请人：BICYCLETX LTD

  公开号：WO2020165600A1

  公开（公告）日：2020-08-20

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。